​

Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MNPR Stock Forecast

Monopar Therapeutics (MNPR) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $118.00, with a high of $125.00 and a low of $105.00. This represents a 9.84% increase from the last price of $107.43.

- $30 $60 $90 $120 $150 High: $125 Avg: $118 Low: $105 Last Closed Price: $107.43

MNPR Stock Rating

Monopar Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 2 Hold (15.38%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 2 11 Strong Sell Sell Hold Buy Strong Buy

MNPR Price Target Upside V Benchmarks

TypeNameUpside
StockMonopar Therapeutics9.84%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2517
Avg Price Target$125.00$115.40$107.24
Last Closing Price$107.43$107.43$107.43
Upside/Downside16.35%7.42%-0.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2649---13
Jun, 2649---13
May, 26410---14
Apr, 26410---14
Mar, 26410---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 23, 2026UBS$125.00$112.4811.13%16.35%
Jul 22, 2026H.C. Wainwright$125.00$112.6310.98%16.35%
Jun 30, 2026BTIG$117.00$94.5623.73%8.91%
Jun 29, 2026UBS$105.00$87.6819.75%-2.26%
Jun 02, 2026Piper Sandler$105.00$64.4063.04%-2.26%
Jan 09, 2026Maxwell SkorMorgan Stanley$115.00$63.4081.39%7.05%
Nov 14, 2025Chris RaymondRaymond James$123.00$87.0141.36%14.49%
Oct 13, 2025Etzer DaroutBarclays$125.00$87.8242.34%16.35%
Oct 06, 2025Raymond James$142.00$99.3942.87%32.18%
Oct 02, 2025Oppenheimer$115.00$84.7335.73%7.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2026H.C. WainwrightBuyBuyhold
Jul 15, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 30, 2026BTIGBuyBuyhold
Jun 29, 2026H.C. WainwrightBuyBuyhold
Jun 02, 2026H.C. WainwrightBuyBuyhold
Jan 21, 2026Cantor FitzgeraldOverweightOverweighthold
Jan 09, 2026Morgan StanleyOverweightinitialise
Jan 07, 2026Raymond JamesOutperformOutperformhold
Nov 14, 2025Raymond JamesStrong BuyOutperformdowngrade
Oct 13, 2025BarclaysOverweightinitialise

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.58$-1.36$-1.85---
Avg Forecast$-3.30$-1.29$-2.38$-1.48$0.53$1.86
High Forecast$-3.30$-1.26$-1.27$0.70$3.17$1.86
Low Forecast$-3.30$-1.31$-3.49$-3.95$-3.69$1.86
Surprise %-82.42%5.43%-22.27%---

Revenue Forecast

$10M $23M $36M $49M $62M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$14.52M$42.50M$70.72M
High Forecast---$14.52M$42.50M$70.72M
Low Forecast---$14.52M$42.50M$70.72M
Surprise %------

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.40M$-15.59M$-13.72M---
Avg Forecast$-47.89M$-18.69M$-34.53M$-15.84M$-8.53M$26.99M
High Forecast$-47.89M$-18.35M$-18.42M$10.16M$46.00M$26.99M
Low Forecast$-47.89M$-19.03M$-50.65M$-57.32M$-53.55M$26.99M
Surprise %-82.45%-16.61%-60.28%---

MNPR Forecast FAQ

Is Monopar Therapeutics stock a buy?

Monopar Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monopar Therapeutics is a favorable investment for most analysts.

What is Monopar Therapeutics's price target?

Monopar Therapeutics's price target, set by 13 Wall Street analysts, averages $118 over the next 12 months. The price target range spans from $105 at the low end to $125 at the high end, suggesting a potential 9.84% change from the previous closing price of $107.43.

How does Monopar Therapeutics stock forecast compare to its benchmarks?

Monopar Therapeutics's stock forecast shows a 9.84% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Monopar Therapeutics over the past three months?

  • July 2026: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Monopar Therapeutics’s EPS forecast?

Monopar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.48, marking a -20.00% decrease from the reported $-1.85 in 2025. Estimates for the following years are $0.53 in 2027, and $1.86 in 2028.

What is Monopar Therapeutics’s revenue forecast?

Monopar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $14.52M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $42.5M, and $70.72M for 2028.

What is Monopar Therapeutics’s net income forecast?

Monopar Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-15.836M, representing an 15.45% increase from the reported $-13.717M in 2025. Projections indicate $-8.525M in 2027, and $26.99M in 2028.